ASTHNasdaqServices-Management Consulting ServicesFiscal year ends December 31
Astrana Health, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$36.90+0.09 (+0.24%)
Close on Oct 19, 2026
- Market cap
- $1.84B
- P/E (TTM)
- 45.0
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2010 to 2025
Gross margin
10.7%−10.8 pts over 5 years
Operating margin
2.5%−9.2 pts over 5 years
Net margin
0.7%−4.8 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +56.4% | +40.6% | +35.9% | – | |
| Gross profit | +25.8% | +19.6% | +18.2% | – | |
| Operating income | -12.1% | -9.0% | -0.5% | – | |
| Net income | -47.9% | -20.7% | -9.8% | – | |
| EPS, diluted | -48.9% | -22.5% | -14.6% | – | |
| Free cash flow | +136.6% | +20.9% | +18.4% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2014 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 337.6% | 14.4% | 3.0% | |
| Return on assets | -139.8% | 4.9% | 1.3% | |
| Current ratio | 0.68 | 2.94 | 1.40 | |
| Debt to equity | 0.00 | 0.73 | 1.33 | |
| Net debt to EBITDA | 0.37× | 0.48× | 4.90× | |
| Interest coverage | -5.8× | 8.5× | 1.6× | |
| Capex to revenue | 0.2% | 0.2% | 0.3% | |
| Diluted shares | 4M | 37M | 49M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Astrana Health generated $387.49M from operations and spent $259.62M on capital expenditure, dividends and share buybacks. 34% of that went back into the business.
Generated
$387.49M
Used
$259.62M
Capital expenditure$88.83M34%Dividends$119.11M46%Share buybacks$51.68M20%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin0.7%
×Asset turnover1.78×
×Equity multiplier2.40×
=Return on equity, FY20253.0%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 0.7% | 1.78× | 2.40× | 3.0% |
| FY2024 | 2.1% | 1.78× | 1.72× | 6.5% |
| FY2023 | 4.4% | 1.46× | 1.64× | 10.5% |
| FY2022 | 3.9% | 1.25× | 1.85× | 9.1% |
| FY2021 | 8.9% | 0.92× | 2.16× | 17.7% |
| FY2020 | 5.5% | 0.89× | 2.96× | 14.4% |
| FY2019 | 2.5% | 0.90× | 3.34× | 7.6% |
| FY2014 | -47.9% | 2.92× | -2.42× | 337.6% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero$22.49M
- Cash generatingOperating cash flow above zero$114.60M
- Return on assets improvedROA up on the prior year4.6% → 1.7%
- Earnings backed by cashOperating cash flow above net income$114.60M vs $22.49M
- Less leverageLong-term debt to assets fell31.4% → 44.7%
- Better liquidityCurrent ratio rose1.75 → 1.40
- No dilutionShare count did not rise48M → 49M
- Gross margin improvedGross margin up on the prior year13.34% → 10.73%
- More efficientAsset turnover rose2.18 → 2.35